RAIN-32
Phase 3Small molecule
RAIN-32 is one of 21 small molecule programs targeting Dedifferentiated Liposarcoma. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Dedifferentiated Liposarcoma
#DrugCompanyPhaseTrials
1Jevtana
SanofiApproved
Verzenio
Eli LillyPhase 3
Adriamycin
PfizerPhase 3
Yondelis
AApotex Inc.
Phase 3
Kisqali
NovartisPhase 2
Dostarlimab
IncytePhase 2
Afinitor
NovartisPhase 2
Libtayo
RegeneronPhase 2
Pemazyre
IncytePhase 2
Ibrance
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RAIN-32. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRain Oncology Inc